RichardFAmbinderMD

Professor of Oncology, Professor of Medicine, Professor of Pathology, Johns Hopkins University School of Medicine; Director, Division of Hematologic Malignancies, Program Leader, Hematologic Malignancies and Bone Marrow Transplant, James B. Murphy Professor

Join to view full profile

Dr. Ambinder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ambinder's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-955-0960

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 1979 - 1982
Johns Hopkins University School of MedicineClass of 1979
Johns Hopkins UniversityFellowship, Medical Oncology

Certifications & Licensure

MD State Medical License 1979 - 2026
VA State Medical License 2023 - 2026
PA State Medical License 2020 - 2022
MI State Medical License 1980 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Elected Member The American Society for Clinical Investigation, 1999
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Valproic Acid in Treating Patients With Kaposi's Sarcoma Start of enrollment: 2005 Feb 01
Completed
Not Applicable
Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD Start of enrollment: 2003 Jan 01
Terminated
Phase 1
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
124I-FIAU Imaging in EBV and KSHV Associated Cancers Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
Completed
Phase 2
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
Allogeneic Transplant in HIV Patients (BMT CTN 0903) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals Start of enrollment: 2013 Jun 01
Completed
Early Phase 1
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
Suspended
Phase 1, Phase 2
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Start of enrollment: 2017 Mar 13
Completed
Phase 2
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST) Start of enrollment: 2020 May 01
Recruiting
Phase 1
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Start of enrollment: 2010 Sep 01
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

165 citations
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
Joseph A. Sparano, Jeannette Y. Lee, Lawrence D. Kaplan, Alexandra M. Levine, Juan Carlos Ramos
Blood. 2010-04-15
33 citations
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
Kathryn Lurain, Ramya Ramaswami, Ralph Mangusan, Anaida Widell, Irene Ekwede
Journal for Immunotherapy of Cancer. 2021-02-01
157 citations
NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun
Journal of the National Comprehensive Cancer Network. 2018-03-01

Abstracts/Posters

Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients
Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
Richard F. Ambinder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Cytomegalovirus Reactivation in Haploidentical Blood or Marrow Transplant (BMT) Using Post-Transplant Cyclophosphamide (PTCy) Is Associated with Higher Non-Relapse-Rel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
5th Annual T-cell Lymphoma Forum
Jonathan Wood & Associates, San Francisco, California - 1/24/2013

Other

Development of malignancy following solid organ transplantation
Ambinder RF, Brennan DC, Rodeheffer RJ
http://www.uptodate.com/contents/development-of-malignancy-following-solid-organ-transplantation
UpToDate, Wolters Kluwer Health - 2013-04-18
The role of Epstein-Barr virus in Hodgkin lymphoma
Ambinder RF
http://www.uptodate.com/contents/the-role-of-epstein-barr-virus-in-hodgkin-lymphoma
UpToDate, Wolters Kluwer Health - 2012-06-26
Systemic therapy for malignancy in patients on anti retroviral medications
Ambinder RF, Flexner CW, Deeken JF, Rudek MA
http://www.uptodate.com/contents/systemic-therapy-for-malignancy-in-patients-on-anti-retroviral-medi
UpToDate, Wolters Kluwer Health - 2012-08-16

Press Mentions

Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin LymphomaDecember 3rd, 2018
HIV-Associated Cancers: A Paradigm Shift?April 19th, 2018
Liquid Biopsies Study Boosts Cancer Detection HopeAugust 17th, 2017
Join now to see all